Tijdens deze podcast spreken we met medische experts over diverse onderwerpen rondom het werken op de IC en infectieziekten-gerelateerde onderwerpen die de patiëntenzorg ondersteunen, leuk, moeilijk en vooral ook interessant kunnen maken. Deze podcastserie is mogelijk gemaakt door Pfizer.
Intensive
Claim This Podcastby Pfizer NL | MIC
30 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇳🇱
Podcast Overview
Tijdens deze podcast spreken we met medische experts over diverse onderwerpen rondom het werken op de IC en infectieziekten-gerelateerde onderwerpen die de patiëntenzorg ondersteunen, leuk, moeilijk en vooral ook interessant kunnen maken. Deze podcastserie is mogelijk gemaakt door Pfizer.
Language
🇳🇱
Publishing Since
6/30/2025
1 verified contact email on file for Intensive
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 2, 2025
'Artificial intelligence for improved infection management in critically ill patients' (Feat. Thomas de Corte)
Thomas de Corte discusses how artificial intelligence can improve infection management for critically ill patients in this interview.
July 2, 2025
Invasieve aspergillose: zin en onzin? (Feat. Simon Feys)
Simon Feys discusses invasive aspergillose, exploring its complexities and clarifying misconceptions in this interview episode.
July 2, 2025
Wel of geen corticosteroiden? (Feat. Rik Endeman & Yves Debaveye)
Rik Endeman and Yves Debaveye discuss the use of corticosteroids, but the specific context or insights remain unclear in this interview episode.
30 total episodes available
Recent guests on Intensive
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Thomas de Corte
Guest
Simon Feys
Guest
Rik Endeman
Guest
Yves Debaveye
Guest
Marco Goeijenbier
Guest
Wim Tissing
Guest
Elizabeth de Kort
Guest
Mark de Boer
Guest
Jennifer Tjon
Guest
Thomas van der Vaart
Guest
Paul Verweij
Guest
Eveline Snelders
Guest
Deep-dive analytics for Intensive
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Intensive?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.